Decoding the Gut's Whisper: Could This Microbial Code Unlock Better MS Care?

What is it about?

Gut health and the microbiome have been increasingly linked to multiple sclerosis (MS), but until now, no microbial marker has been able to consistently work across different microbiome studies due to the heterogeneous nature of microbiome findings. In our study, we identified the Bifidobacterium to Akkermansia (BA:AM) ratio as a potential microbial marker for MS severity, providing a more reliable and consistent approach. This ratio was validated in both our MS cohort and a larger independent global cohort. Interestingly, we found that Blautia, which is enriched in MS, promoted the growth of Akkermansia, resulting in a lower BA:AM ratio, as observed in both MS patients and animal models. This shift in the microbiome led to gut inflammation, further highlighting the role of specific bacterial communities in MS pathogenesis. This research offers new insights into how microbial imbalances influence MS and could pave the way for future diagnostic and therapeutic strategies.

Featured Image

Photo by julien Tromeur on Unsplash

Photo by julien Tromeur on Unsplash

Why is it important?

We've discovered that the balance of certain bacteria in the gut can tell us a lot about multiple sclerosis (MS). Specifically, the ratio of Bifidobacterium adolescentis to Akkermansia muciniphila seems to change not only when MS is present, but also with the severity of the disease. This was confirmed in both our study and a large global study. Think of it like a garden: if the balance of plants changes, it can tell you about the health of the garden and how sick it is. Similarly, the balance of gut bacteria changes with MS. This research opens up new possibilities for using gut bacteria to help diagnose MS and track how it progresses.

Perspectives

“

This study highlights the strong connection between gut health and MS. The ratio of certain gut bacteria (e.g. Bifidobacetrium to Akkermansia) could serve as a potential biomarker for tracking disease severity and progression, offering a new way to monitor MS. Our findings also suggest that modifying the gut microbiome—through diet, probiotics, or other targeted approaches—might help restore balance and influence disease outcomes. However, it’s important to avoid labeling gut bacteria as strictly "good" or "bad." Their effects depend on context—Akkermansia muciniphila, for example, is linked to benefits in obesity but appears to promote inflammation in MS. Understanding these microbial interactions could open new doors for diagnosing, monitoring, and potentially treating MS in the future.

”